2,115 press releases in English indexed under biotech & pharma.
For Trade and Medical Media Only CAMBRIDGE, England, October 22, 2026--Today Mundipharma announced additional results from the global Phase III ReSPECT clinical trial evaluating REZZAYO ® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic hae
The Alzheimer's disease competitive landscape report delivers important insights into approved as well as ongoing research on 240+ pipeline Alzheimer's disease drugs, clinical strategies, upcoming therapeutics, and commercial analysis. The Alzheimer's disease competitive landscape report delivers important insights into approved as well as ongoing research on 240+ pipeline Alzheimer's disease drugs, clinical strategies, upcoming therapeutics, and commercial analysis.
Risk-Based Monitoring System Market Report The Business Research Company The Business Research Company’s Risk-Based Monitoring System Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 LONDON, GREATER LONDON, UNITED KINGDOM, October 22, 2026 / EINPresswire.com / -- The risk-based monitoring system market is seeing rapid development driven by the evolving needs of clinical trials and regulatory de
Jena, Germany, Oct. 22, 2026 -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the presentation of new pre-clinical data on izicopan in renal disease models at the American Society of Nephrology’s Kidney Week 2026, taking place in Denver, Colorado, October 21 - 25. The in vivo and in vitro data demonstrated that izicopan robustly inhibited C5aR-mediated inflammatory responses and provided renal protection, supporting its potential as a therapeutic candidate for complement-driven kidney diseases.
Research published in the journal Brain Stimulation details first comprehensive, surgically relevant map of human vagus nerve's organ-specific branches MANHASSET, N.Y., October 22, 2026--For too long, harnessing the therapeutic potential of the vagus nerve has been like navigating uncharted waters. Now
PleoPharma presents research survey findings characterizing women's experiences with frequent cannabis use, cessation efforts, and cannabis withdrawal symptoms. PHOENIXVILLE, Pa., Oct. 22, 2026 -- PleoPharma, Inc., a clinical-stage development company focused on...
Precision lymphatic targeting platform validated with clinical data in both Rheumatoid Arthritis and in Cancer; Class II Device FDA submission planned in Q2 2027. NEW YORK, October 22, 2026--Sofusa Holdings today announced its launch as an independent, clinical-stage company pioneering the development
Dublin, Oct. 22, 2026 -- "Frontotemporal Dementia - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.
DURAVYU’s Phase 3 LUCIA trial missed its primary endpoint and EYPT shares lost nearly 80% of their value in a single session. Levi & Korsinsky is investigating on behalf of shareholders who may have legal rights arising from those losses DURAVYU’s Phase 3 LUCIA trial missed its primary endpoint and EYPT shares lost nearly 80% of their value in a single session. Levi & Korsinsky is investigating on behalf of shareholders who may have legal rights arising from those losses
Track Charcot-Marie-Tooth pipeline innovation, from first-in-class therapies to gene therapy, with clinical progress, unmet needs, collaborations, licensing and M&A insights Track Charcot-Marie-Tooth pipeline innovation, from first-in-class therapies to gene therapy, with clinical progress, unmet needs, collaborations, licensing and M&A insights
Dublin, Oct. 22, 2026 -- "Postpartum Depression - Pipeline Insight, 2026" has been added to ResearchAndMarkets.com's offering.
Explore the Polycythemia Vera pipeline with drug profiles, therapeutic assessments, unmet needs, collaborations, licensing, and inactive candidates Explore the Polycythemia Vera pipeline with drug profiles, therapeutic assessments, unmet needs, collaborations, licensing, and inactive candidates